Our findings are consistent with previous findings that show that elevated levels of liver enzymes (including ALT and AST) are associated with increased liver disease mortality [34], and that patients with NAFLD and elevated liver enzyme levels (ALT and AST levels) display significantly higher risk for cirrhosis and hepatocellular carcinoma [35]. This evidence concerns the gene GPT and metabolic dysfunction-associated steatotic liver disease.